Search results
Results from the WOW.Com Content Network
HIV Drug Resistance Database, also known as Stanford HIV RT and Protease Sequence Database, is a database at Stanford University that tracks 93 common mutations of HIV.It has been recompiled in 2008 listing 93 common mutations, after its initial mutation compilation in 2007 of 80 mutations.
The Stanford HIV RT and Protease Sequence Database (also called the “HIV Drug Resistance Database”) was formed in 1998 with HIV reverse transcriptase and protease sequences from persons with well-characterized antiretroviral treatment histories, and is publicly available to query resistance mutations and genotype-treatment, genotype ...
TDR Targets: a chemogenomics database focused on drug discovery in tropical diseases; TRANSFAC: a database about eukaryotic transcription factors, their genomic binding sites and DNA-binding profiles; JASPAR: a database of manually curated, non-redundant transcription factor binding profiles.
HIV drug resistance poses an issue because it reduces the possible HIV medications a person can take due to cross resistance. In cross resistance, an entire class of medication is considered ineffective in lowering a patient's HIV viral load because all the drugs in a given class share the same mechanism of action. [ 7 ]
NAHDAP's staff consists of professional researchers, data archivists and technicians working together to obtain, process, distribute, and promote amongst social science researchers sharing of data relevant to drug addiction and HIV. NAHDAP is a project of the National Institute on Drug Abuse, part of the National Institutes of Health.
Resistance Database Initiative Logo. HIV Resistance Response Database Initiative (RDI) was formed in 2002 to use artificial intelligence (AI) to predict how patients will respond to HIV drugs using data from more 250,000 patients from around 50 countries around the world.
As a result, lamivudine was identified as a less toxic agent to mitochondria DNA than other retroviral drugs. [18] [19] Lamivudine was approved by the US Food and Drug Administration (FDA) in November 1995, for use with zidovudine (AZT) and again in 2002. It is on the World Health Organization's List of Essential Medicines. [10]
Research to improve current treatments includes decreasing side effects of current drugs, further simplifying drug regimens to improve adherence, and determining better sequences of regimens to manage drug resistance. There are variations in the health community in recommendations on what treatment doctors should recommend for people with HIV.